NEW YORK, June 30, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Bristol-Myers Squibb Company (NYSE: BMY), Allergan Inc. (NYSE: AGN), CR Bard Inc. (NYSE: BCR), Perrigo Co. (NYSE: PRGO) and Health Net, Inc. (NYSE: HNT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4241-100free.

-- Bristol-Myers Squibb Company Analyst Notes On June 24, 2014, Bristol-Myers Squibb Company (Bristol-Myers) announced that it is collaborating with Duke University through its Duke Clinical Research Institute (DCRI) focused on clinical trial transparency. According to the Company, the collaboration with DCRI aims to support data sharing and enhance the Company's existing policies on transparency and disclosure of clinical trial information. "Bristol-Myers Squibb's collaboration with DCRI reflects our commitment to providing broader, more timely access to important clinical trial information and serves as a catalyst to strengthening public confidence in medicines, advancing science and improving public health," said Francis Cuss, MB BChir, FRCP, EVP and CSO, Bristol-Myers Squibb. The full analyst notes on Bristol-Myers are available to download free of charge at:

http://www.analystsreview.com/Jun-30-2014/BMY/report.pdf

-- Allergan Inc. Analyst Notes On June 23, 2014, Allergan, Inc. (Allergan) announced that its Board of Directors has unanimously reached the decision that Valeant Pharmaceuticals International Inc.'s (Valeant) unsolicited exchange offer to acquire all outstanding common shares of Allergan is not in the best interest of the Company and its stockholder, as the offer is grossly inadequate, substantially undervalues the Company, and creates significant risks and uncertainties for Allergan stockholders. Accordingly, the Board strongly recommends Allergan stockholders to not tender any Company shares to Valeant. David E.I. Pyott, Allergan's Chairman of the Board and CEO commented, "The Board strongly recommends that Allergan stockholders reject Valeant's exchange offer and prevent Valeant from taking control of Allergan at a price that does not appropriately reflect the underlying value of Allergan's assets, operations and prospects, including our industry-leading position and projected growth opportunities." The full analyst notes on Allergan are available to download free of charge at:

http://www.analystsreview.com/Jun-30-2014/AGN/report.pdf

-- CR Bard Inc. Analyst Notes On June 11, 2014, CR Bard Inc. (Bard) announced that its Board of Directors has authorized a quarterly dividend on the Company's common stock in the amount of $0.22 per share. Representing a 5% growth, the aforesaid dividend is payable on August 1, 2014, to shareholders of record at the close of the business on July 21, 2014. The full analyst notes on Bard are available to download free of charge at:

http://www.analystsreview.com/Jun-30-2014/BCR/report.pdf

-- Perrigo Co. Analyst Notes On June 20, 2014, Perrigo Company plc (Perrigo), together with Catalent, announced that the two have settled their first to file Hatch Waxman litigation with Teva with respect to a generic version of Proair(R) HFA. Pursuant to the settlement agreement, Perrigo has a limited quantity license to launch a generic version of Proair(R) HFA starting on December 19, 2016 (or earlier in certain circumstances) and an unlimited quantity license beginning after June 30, 2018. Perrigo's Chairman, President and CEO Joseph C. Papa commented, "This product was the result of the continued hard work and dedication of our Perrigo Rx team. This agreement is another example of Perrigo's investment and commitment to making quality healthcare more affordable for consumers." Proair(R) HFA indicated in patients 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm. The full analyst notes on Perrigo are available to download free of charge at:

http://www.analystsreview.com/Jun-30-2014/PRGO/report.pdf

-- Health Net, Inc. Analyst Notes On June 25, 2014, Health Net, Inc. (Health Net) stock increased slightly by 2.69% to end the day at $40.90 compared to the previous day's closing price of $39.83. The Company's stock has increased 2.27% over the past five trading days compared to Standard & Poor's 500 which has grown 0.13% during the same time period. The Dow Jones Industrial Average however declined 0.23% over the last five days of trade. The full analyst notes on Health Net are available to download free of charge at:

http://www.analystsreview.com/Jun-30-2014/HNT/report.pdf

-- About Analysts Review We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

=============== EDITOR'S NOTES: ===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com [http://www.analystsreview.com ].

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com [http://www.analystsreview.com ].

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com [http://www.analystsreview.com ] for consideration.

COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Analysts Review